These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 14621044)

  • 61. Substitution of cyclophosphamide and busulfan by fludarabine, treosulfan and melphalan in a preparative regimen for children and adolescents with Shwachman-Diamond syndrome.
    Sauer M; Zeidler C; Meissner B; Rehe K; Hanke A; Welte K; Lohse P; Sykora KW
    Bone Marrow Transplant; 2007 Feb; 39(3):143-7. PubMed ID: 17211437
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Allogeneic stem cell transplantation following non-myeloablative conditioning: favorable results in 21 high risk patients with hematological malignancies treated in the Utrecht University Medical Center, the Netherlands].
    Petersen EJ; Lokhorst HL; Verdonck LF
    Ned Tijdschr Geneeskd; 2003 Nov; 147(47):2328-32. PubMed ID: 14669540
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?
    Chunduri S; Dobogai LC; Peace D; Saunthararajah Y; Quigley J; Chen YH; Mahmud N; Hurter E; Beri R; Rondelli D
    Bone Marrow Transplant; 2008 Jun; 41(11):935-40. PubMed ID: 18264144
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A fludarabine-based protocol for bone marrow transplantation in Fanconi's anemia.
    Kapelushnik J; Or R; Slavin S; Nagler A
    Bone Marrow Transplant; 1997 Dec; 20(12):1109-10. PubMed ID: 9466288
    [TBL] [Abstract][Full Text] [Related]  

  • 65. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2.
    Chae YS; Sohn SK; Kim JG; Cho YY; Moon JH; Shin HJ; Chung JS; Cho GJ; Yang DH; Lee JJ; Kim YK; Kim HJ
    Bone Marrow Transplant; 2007 Sep; 40(6):541-7. PubMed ID: 17637692
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Urgent allogeneic bone marrow transplantation using a preparative regimen of cyclophosphamide anti-human thymocytes rabbit globulin in a patient with severe aplastic anemia with pneumonia].
    Okamoto T; Marumo M; Saheki K; Okada M; Kawaguchi K; Takatuka H; Fujimori Y; Takemoto Y; Kohsaki M; Kanamaru A; Kakishita E
    Rinsho Ketsueki; 1996 Jan; 37(1):72-6. PubMed ID: 8683872
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation.
    Chunduri S; Dobogai LC; Peace D; Saunthararajah Y; Chen HY; Mahmud N; Quigley J; Hoffman R; Jessop E; Beri R; Rondelli D
    Bone Marrow Transplant; 2006 Oct; 38(7):477-82. PubMed ID: 16980995
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Fludarabine-based disease-specific conditioning or conventional myeloablative conditioning in hematopoietic stem cell transplantation for treatment of non-malignant diseases.
    Ringdén O; Remberger M; Svenberg P; Svahn BM; Dahllöf G; Gustafsson B; Hassan Z; Omazic B; Uzunel M; Aschan J; Barkholt L; Winiarski J; Ljungman P; Mattsson J
    Bone Marrow Transplant; 2007 Apr; 39(7):383-8. PubMed ID: 17310137
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Graft rejection and hyperacute graft-versus-host disease in stem cell transplantation from non-inherited maternal-antigen-complementary HLA-mismatched siblings.
    Okumura H; Yamaguchi M; Kotani T; Sugimori N; Sugimori C; Ozaki J; Kondo Y; Yamazaki H; Chuhjo T; Takami A; Ueda M; Ohtake S; Nakao S
    Eur J Haematol; 2007 Feb; 78(2):157-60. PubMed ID: 17313562
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Allogeneic peripheral blood stem cell transplantation following fludarabine-based conditioning in six children with advanced Hodgkin's disease.
    Claviez A; Klingebiel T; Beyer J; Nürnberger W; Ehninger G; Suttorp M; Dreger P; Dörffel W; Schmitz N
    Ann Hematol; 2004 Apr; 83(4):237-41. PubMed ID: 14625790
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning regimen.
    Maury S; Bacigalupo A; Anderlini P; Aljurf M; Marsh J; Socié G; Oneto R; Passweg JR;
    Haematologica; 2009 Sep; 94(9):1312-5. PubMed ID: 19734425
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparable outcomes between younger (⩽40 years) and older (>40 years) adult patients with severe aplastic anemia after HLA-matched sibling stem cell transplantation using fludarabine-based conditioning.
    Shin SH; Jeon YW; Yoon JH; Yahng SA; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Kim HJ; Cho SG; Kim DW; Min WS; Lee JW
    Bone Marrow Transplant; 2016 Nov; 51(11):1456-1463. PubMed ID: 27348538
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
    Lee KH; Lee JH; Lee JH; Kim DY; Kim SH; Shin HJ; Lee YS; Kang YA; Seol M; Ryu SG
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Matched sibling donor stem cell transplantation for Fanconi anemia patients with T-cell somatic mosaicism.
    Yabe M; Shimizu T; Morimoto T; Koike T; Takakura H; Tsukamoto H; Muroi K; Oshima K; Asami K; Takata M; Yamashita T; Kato S; Yabe H
    Pediatr Transplant; 2012 Jun; 16(4):340-5. PubMed ID: 22404423
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies.
    Hamaki T; Kami M; Kim SW; Onishi Y; Kishi Y; Murashige N; Hori A; Kojima R; Sakiyama M; Imataki O; Heike Y; Tanosaki R; Masuo S; Miyakoshi S; Taniguchi S; Tobinai K; Takaue Y
    Bone Marrow Transplant; 2004 May; 33(9):891-900. PubMed ID: 15048142
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Alkylator-free conditioning regimen for patients with acquired aplastic anemia, transplanted from genetically identical twins.
    Trakhtman P; Balashov D; Shipicina I; Skvortsova Y; Shelikhova L; Filimonov A; Novichkova G; Skorobogatova E; Maschan M; Maschan A
    Pediatr Transplant; 2007 Aug; 11(5):572-4. PubMed ID: 17631032
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Fludarabine allows dose reduction for total body irradiation in pediatric hematopoietic stem cell transplantation.
    Kornguth DG; Mahajan A; Woo S; Chan KW; Antolak J; Ha CS
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(4):1140-4. PubMed ID: 17379444
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.
    Saito AM; Kami M; Mori S; Kanda Y; Suzuki R; Mineishi S; Takami A; Taniguchi S; Takemoto Y; Hara M; Yamaguchi M; Hino M; Yoshida T; Kim SW; Hori A; Ohashi Y; Takaue Y
    Am J Hematol; 2007 Oct; 82(10):873-80. PubMed ID: 17570513
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning.
    Grigg AP; Gibson J; Bardy PG; Reynolds J; Shuttleworth P; Koelmeyer RL; Szer J; Roberts AW; To LB; Kennedy G; Bradstock KF
    Biol Blood Marrow Transplant; 2007 May; 13(5):560-7. PubMed ID: 17448915
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.